Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4221787 A
Publication typeGrant
Application numberUS 06/059,380
Publication dateSep 9, 1980
Filing dateJul 20, 1979
Priority dateMar 28, 1978
Publication number059380, 06059380, US 4221787 A, US 4221787A, US-A-4221787, US4221787 A, US4221787A
InventorsNicholas S. Bodor, Kenneth B. Sloan
Original AssigneeInterx Research Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Esteramide prodrugs of anti-inflammatory corticosteroids
US 4221787 A
Abstract
Transient, C-21 and/or C-17 esteramide prodrugs of the anti-inflammatory corticosteroids, prepared by esterification of hydroxy steroids, are disclosed.
Images(14)
Previous page
Next page
Claims(86)
What is claimed is:
1. A compound having the structural formula: ##STR19## wherein R1 and R2, which can be the same or different, are each H, ##STR20## or ##STR21## with the proviso that at least one of R1 and R2 is ##STR22## or ##STR23## R3 is H, F or Cl; R4 is H, CH3, F or Cl;
R5 is H, CH3 or OH; or OR2 and R5 can together form a cyclic ketal;
R6 and R7, which can be the same or different, are each H, C1 -C8 alkyl or ##STR24## or R6 and R7, together with the nitrogen atom from which they both depend, can form a 5- or 6-membered N-heterocycle or a 5- or 6-membered N,O-heterocycle;
R8 is C1 -C20 alkyl, C2 -C20 alkenyl, C3 -C7 cycloalkyl, phenyl, (C1 -C4 alkyl substituted)phenyl or C1 -C20 alkyl-C6 -C10 aryl;
X is OH or ═O;
Y is --(CH2)n, wherein n ranges from 1 to 8, --(CH2)m Z --(CH2)n, wherein both n and m range from 1 to 8, C3 -C7 cycloalkyl or phenyl;
Z is O or S; and
the dotted line indicates the optional presence of a 1,2-double bond.
2. A compound as defined by claim 1 wherein R1 is ##STR25## wherein Y, R6 and R7 are as defined in claim 1.
3. A compound as defined by claim 1 wherein R1 is ##STR26## wherein R6 is as defined in claim 1.
4. A compound as defined by claim 2 or 3 wherein R2 is H.
5. A compound as defined by claim 2 or 3 wherein R2 is ##STR27## wherein R8 is C1 -C20 alkyl.
6. A compound as defined by claim 1 wherein R2 is ##STR28## wherein Y, R6 and R7 are as defined in claim 1.
7. A compound as defined in claim 1 wherein R2 is ##STR29## wherein R6 is as defined in claim 1.
8. A compound as defined by claim 6 or 7 wherein R1 is H.
9. A compound as defined by claim 6 or 7 wherein R1 is ##STR30## wherein R8 is C1 -C20 alkyl.
10. A compound as defined by claim 1, 2, 3, 6 or 7 wherein X is β-OH.
11. A compound as defined by claim 2 wherein Y is --(CH2)n.
12. A compound as defined by claim 6 wherein Y is --(CH2)n.
13. A compound as defined by claim 1 wherein R3 is H.
14. A compound as defined by claim 1 wherein R3 is F.
15. A compound as defined by claim 1 wherein R4 is H.
16. A compound as defined by claim 1 wherein R4 is F.
17. A compound as defined by claim 1, 2 or 3 wherein R5 is H.
18. A compound as defined by claim 1, 2 or 3 wherein R5 is CH3.
19. A compound as defined by claim 1, 2 or 3 wherein R5 is OH.
20. A compound as defined in claim 1, 2 or 3 wherein OR2 and R5 together form isopropylidenedioxy or benzylidenedioxy.
21. A compound as defined in claim 1, 2 or 3 wherein X is ═O.
22. A compound as defined in claim 1 wherein R1 is ##STR31## and the remainder of the structural variables are identical to those of a known anti-inflammatory steroid selected from the group consisting of cortisone, hydrocortisone, hydrocortisone 17-butyrate, hydrocortisone 17-valerate, triamcinolone, triamcinolone acetonide, prednisone, prednisolone, methyl prednisolone, paramethasone, meprednisone, fluocinolone acetonide, fluprednisolone, flumethasone, dexamethasone, desonide, chloroprednisone, betamethasone, amcinafide, amcinafal and flurandrenolone acetonide.
23. A compound as defined by claim 1, the same being 4-pregene-11β,17α-dihydroxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione.
24. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
25. A compound as defined by claim 1, the same being 4-pregene-11β,17α-dihydroxy-21-(N,N-dipropylsucinamyloxy)-3,20-dione.
26. A compound as defined by claim 1, the same being 4-pregene-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione.
27. A compound as defined by claim 1, the same being 4-pregene-11β,17α-dihydroxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione.
28. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione.
29. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione.
30. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione.
31. A compound as defined in claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione.
32. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione.
33. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione.
34. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
35. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
36. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
37. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylglutaramyloxy)-32,0-dione.
38. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione.
39. A compound as defined by claim 1, the same being 4-pregnene-11β, 17α-dihydroxy-21-(N,N-diethylsebacamyloxy)-3,20-dione.
40. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-(N,N-dimethylsuccinamyloxy)-3,20-dione.
41. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione.
42. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione.
43. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione.
44. A compound as defined by claim 1, the same being 4-pregnene-17α-hydroxy-21-(N,N-dioctylsuccinamyloxy)-3,11,20-trione.
45. A compound as defined by claim 1, the same being 4-pregnene-17α-hydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,11,20-trione.
46. A compound as defined by claim 1, the same being 4-pregnene-17α-hydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,11,20-trione.
47. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β,17α-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione.
48. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione.
49. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione.
50. A compound as defined by claim 1, the same being 1,4-pregnadiene-17α-hydroxy-21-(2'-oxo-pyrrolidin-5'-yl)carbonyloxy-3,11,20-trione.
51. A compound as defined by claim 1, the same being 1,4-pregnadiene-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione.
52. A compound as defined by claim 1, the same being 1,4-pregnadiene-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione.
53. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,16α-dihydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
54. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethylglutaramyloxy)-3,20-dione.
55. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione.
56. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione.
57. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
58. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dipropylsuccinamyloxy)-3,20-dione.
59. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,17α-dihydroxy-16α-methyl-21-(N,N-diethylsebacamyloxy)-3,20-dione.
60. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-dimethylsuccinamyloxy)-3,20-dione.
61. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-diethylsuccinamyloxy)-3,20-dione.
62. A compound as defined by claim 1, the same being 4-pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione.
63. A compound as defined by claim 1, the same being 4-pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione.
64. A compound as defined by claim 1, the same being 4-pregnene-9α-fluoro-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione.
65. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione.
66. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione.
67. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione.
68. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-[N,N-(3'-oxapentamethylene)-succinamyloxy]-3,20 -dione.
69. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione.
70. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11α,17.alpha.-dihydroxy-21-N,N-dibenzylsuccinamyloxy)-3,20-dione.
71. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione
72. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethylglutaramyloxy)-3,20-dione.
73. A compound as defined by claim 1, the same being 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethyladipamyloxy)-3,20-dione.
74. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
75. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
76. A compound as defined by claim 1, the same being 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
77. A compound as defined by claim 1, the same being 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethyl-3'-oxaglutaramyloxy)-3,20-dione.
78. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-17α-butyryloxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione.
79. A compound as defined by claim 1, the same being 1,4-pregnadiene-27α-hydroxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione.
80. A compound as defined by claim 1, the same being 1,4-pregnadiene-11β,17α-dihydroxy-9α-fluoro-16α-methyl-21-(N,N-diethylsuccinamyloxy)-3,20-dione.
81. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione.
82. A compound as defined by claim 1, the same being 4-pregnene-11β,21-dihydroxy-17α-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione.
83. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-17α,21-bis(N,N-diethylsuccinamyloxy)-3,20-dione.
84. A compound as defined by claim 1, the same being 4-pregnene-11β-hydroxy-21-(N,N-diethylsuccinamyloxy)-17α-[N,N-(N'-methyl-3'-azapentamethylene)-succinamyloxy]-3,20-dione.
85. A pharmaceutical composition of matter comprising an anti-inflammatory effective amount of a compound as defined by claim 1, and a pharmaceutically acceptable inert carrier.
86. A method for alleviating inflammation in or on a warm-blooded animal exhibiting an inflammatory response, which comprises administering thereto an anti-inflammatory effective amount of a compound as defined by claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of our earlier copending application, Ser. No. 891,050, filed Mar. 28, 1978, now abandoned assigned to the assignee hereof and hereby expressly incorporated by reference in its entirety and relied upon.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to certain selected transient prodrug forms of conventional anti-inflammatory steroids [e.g., cortisone, hydrocortisone, prednisone, prednisolone, etc.] useful in alleviating inflammatory conditions in warm-blooded animals.

For purposes of this application, the term "prodrug" denotes a derivative of a known and proven prior art anti-inflammatory steroid compound [e.g., cortisone, hydrocortisone, prednisone, prednisolone, etc.], which derivative, when administered to a warm-blooded animal, "cleaves" in such a manner as to release the proven drug form at its target site or sites of activity.

The term "transient" denotes enzymatic and/or chemical hydrolytic "cleavage" of the compounds of the instant invention in a manner such that the proven drug form [the conventional anti-inflammatory steroid, e.g., cortisone, hydrocortisone, prednisone, prednisolone, etc.] is released, while the remaining "cleaved" moiety remains nontoxic and is metabolized in such a manner that nontoxic, metabolic products are produced.

Finally, the term "pharmaceutically acceptable acid addition salt" as used herein generally includes the nontoxic acid addition salts of selected compounds of formula [I], formed with nontoxic inorganic or organic acids. For example, the salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycollic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, fumaric, sulfonic, toluenesulfonic, and the like.

BACKGROUND OF THE PRIOR ART

Conventional anti-inflammatory steroids, such as cortisone, hydrocortisone, prednisone, prednisolone, etc., are high molecular weight steroidal compounds containing a number of hydrophilic functions, e.g., hydroxyl and keto functions. These compounds are characterised as having (1) extremely low water solubility, (2) extensive intermolecular hydrogen bonding due to the combination of hydrophilic functions, such as --OH and ═O [as evidenced by their high melting point], and (3) high molecular weight.

All three points enumerated above contribute to the inefficient and slow penetrability of these conventional steroidal compounds through biological barriers, among which the most important are (i) the skin and (ii) the gastrointestinal wall.

It is recognized that in the case of the skin, the higher molecular weight anti-inflammatory steroids are absorbed primarily through the appendages and the hair follicles as opposed to the more efficient molecular intercellular absorption. See, M. Katz and B. J. Poulsen, "Absorption of Drugs through the Skin", [Handbook of Experimental Pharmacology, Vol. XXVII/I, Chapter 7, page 104, Springer Verlag, Berlin-Heidelberg-New York (1971).

It too is art recognized that (4) a serious side effect of certain of the known anti-inflammatory steroids is the decrease in thickness, or atrophy, of the skin at the site of application; (5) another adverse effect is a deleterious, systemic side effect on the thymus gland; and (6) in certain instances, with certain of the, e.g., hydrocortisone derivatives, the reduction of inflammation is inadequate.

In view of the foregoing, it is apparent that a serious need exists for a class of novel anti-inflammatory steroidal compounds which will overcome the aforementioned inefficiencies such that penetration of the same through biological barriers will be enhanced, such that less atrophy results, such that less effect on the thymus gland is evidenced, and such that inflammation is reduced to the comparable extent of the highly potent triamcinolone acetonide.

BRIEF SUMMARY OF THE INVENTION

It is one object of the present invention to provide prodrug forms of conventional anti-inflammatory steroids which possess the capability of efficiently penetrating the biological barriers of warm-blooded animals, and, especially, the skin and the gastrointestinal wall.

Another object is the provision of prodrugs of conventional anti-inflammatory steroids which cause less atrophy and systemically affect the thymus to a much lesser degree, but which, nonetheless, remain highly potent.

It is another object of the present invention to provide such prodrug forms of conventional anti-inflammatory compounds which, following administration, will "cleave" in such a manner as to enable the original parent steroidal moiety [e.g., cortisone, hydrocortisone, prednisone, prednisolone, etc.] to be released at its therapeutic site or sites of anti-inflammatory activity and to further permit the cleaved moiety(ies) unassociated with the parent steroidal moiety to be metabolized in a nontoxic fashion.

All the foregoing objects are achieved by topically or orally administering to a warm-blooded animal afflicted with inflammation, a therapeutically effective anti-inflammatory amount of a compound having the structural formula: ##STR1## wherein R1 and R2, which can be the same or different, are each H, ##STR2## or ##STR3## with the proviso that at least one of R1 and R2 is ##STR4## R3 is H, F or Cl; R4 is H, CH3, F or Cl;

R5 is H, CH3 or OH;

R6 and R7, which can be the same or different,

are each H, C1 -C8 alkyl or ##STR5## or R6 and R7, together with the nitrogen atom from which they both depend can form an N-heterocycle or N,O-heterocycle, (e.g., a 5- or 6-membered N-heterocycle or a 5- or 6-membered N,O-heterocycle, such as piperidine, morpholine, pyridine, piperazine, N-methylpiperazine, pyrrolidine, and the like);

R8 is C1 -C20 alkyl, C2 -C20 alkenyl, C3 -C7 cycloalkyl, phenyl, (C1 -C4 alkyl substituted)phenyl or C1 -C20 alkyl-C6 -C10 aryl;

X is OH, e.g., β-OH, or ═O;

Y is --CH2)n , wherein n ranges from 1 to 8, --CH2)m Z--CH2)n, wherein both n and m range from 1 to 8, C3 -C7 cycloalkyl or phenyl;

Z is O or S; and

the dotted line indicates the optional presence of a 1,2-double bond.

Additionally, when R2 is H and R5 is OH, the corresponding cyclic ketal also is envisaged, e.g., acetonide (isopropylidenedioxy) or benzylidenedioxy. Further compare those cyclic ketal forming reactants, herein expressly incorporated by reference, in our U.S. Pat. No. 4,069,322 assigned to the assignee hereof.

DETAILED DESCRIPTION OF THE INVENTION

While all of the compounds encompassed within the above generic formula [I] essentially satisfy the objectives of the invention, nevertheless, certain selected compounds as are set forth immediately below, remain preferred:

[1] 4-Pregnene-11β,7α-dihydroxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione;

[2] 4-Pregene-11β,7α-dihydroxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[3] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dipropylsuccinamyloxy)-3,20-dione;

[4] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione;

[5] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione;

[6] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione;

[7] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione;

[8] 4-Pregnene-11β,17α-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione;

[9] 4-Pregnene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione;

[10] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione;

[11] 4-Pregnene-11β,7α-dihydroxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione;

[12] 4-Pregnene-11β-hydroxy-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[13] 4-Pregnene-11β-hydroxy-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[14] 4-Pregnene-11β-hydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[15] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-diethylglutaramyloxy)-3,20-dione;

[16] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione;

[17] 4-Pregnene-11β,17α-dihydroxy-21-(N,N-diethylsebacamyloxy)-3,20-dione;

[18] 4-Pregnene-11β,21-dihydroxy-17α-(N,N-dimethylsuccinamyloxy)-3,20-dione;

[19] 4-Pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione;

[20] 4-Pregnene-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione;

[21] 4-Pregnene-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione;

[22] 4-Pregnene-17α-hydroxy-21-(N,N-dioctylsuccinamyloxy)-3,11,20-trione;

[23] 4-Pregnene-17α-hydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,11,20-trione;

[24] 4-Pregnene-17α-hydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,11,20-trione;

[25] 1,4-Pregnadiene-11β,17α-dihydroxy-21-[N,N-3'-oxapentamethylene)succinamyloxy]-3,20-dione;

[26] 1,4-Pregnadiene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione;

[27] 1,4-Pregnadiene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione;

[28] 1,4-Pregnadiene-17α-hydroxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,11,20-trione;

[29] 1,4-Pregnadiene-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione;

[30] 1,4-Pregnadiene-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione;

[31] 1,4-Pregnadiene-9α-fluoro-11β,16α-dihydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[32] 1,4-Pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethylglutaramyloxy)-3,20-dione;

[33] 1,4-Pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione;

[34] 1,4-Pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione;

[35] 1,4-Pregnadiene-9α-fluoro-11β-hydroxy-16,α,17α-isopropylidenedioxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[36] 1,4-Pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dipropylsuccinamyloxy)-3,20-dione;

[37] 1,4-Pregnadiene-9α-fluoro-11β,17α-dihydroxy-16α-methyl-21-(N,N-diethylsebacamyloxy)-3,20-dione;

[38] 1,4-Pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-dimethylsuccinamyloxy)-3,20-dione;

[39] 1,4-Pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-diethylsuccinamyloxy)-3,20-dione;

[40] 4-Pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione;

[41] 4-Pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione;

[42] 4-Pregnene-9α-fluoro-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione;

[43] 1,4-Pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione;

[44] 1,4-Pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione;

[45] 1,4-Pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione;

[46] 1,4-Pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione;

[47] 1,4-Pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)-succinamyloxy]-3,20-dione;

[48] 1,4-Pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione;

[49] 1,4-Pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione;

[50] 1,4-Pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethylglutaramyloxy)-3,20-dione;

[51] 1,4-Pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethyladipamyloxy)-3,20-dione;

[52] 1,4-Pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[53] 1,4-Pregnadiene-9α-fluoro-11α-hydroxy-16β-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[54] 1,4-Pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione;

[55] 4-Pregnene-11β,21-dihydroxy-17α-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione;

[56] 4-Pregnene-11β-hydroxy-17α,21-bis(N,N-diethylsuccinamyloxy)-3,20-dione; and

[57] 4-Pregnene-11β-hydroxy-21-(N,N-diethylsuccinamyloxy)-17α-[N,N-(N'-methyl-3'-azapentamethylene)-succinamyloxy-3,20-dione.

A preferred group of compounds of the present invention consists of the compounds of formula [I] wherein at least one of R1 and R2 is ##STR6## or ##STR7## wherein Y, R6 and R7 are defined as hereinabove, and the remainder of the structural variables are identical to those found in one of the following known anti-inflammatory steroids: cortisone, hydrocortisone, hydrocortisone 17-butyrate, hydrocortisone 17-valerate, triamcinolone, triamcinolone acetonide, prednisone, prednisolone, methyl prednisolone, paramethasone, meprednisone, fluocinolone acetonide, fluprednisolone, flumethasone, dexamethasone, desonide, chloroprednisone, betamethasone, amcinafide, amcinafal, and flurandrenolone acetonide. Compounds of formula [I] wherein R1 is ##STR8## are especially preferred, particularly when the remaining structural variations correspond to those of the aforementioned known anti-inflammatory agents, and most especially when R2 is H and R5 is H or OH, or when OR2 and R5 together form a cyclic ketal such as the acetonide structure.

The compounds of the present invention can be prepared by known methods. Thus, the compounds of formula [I] wherein R1 is ##STR9## or ##STR10## can be conveniently prepared by esterification of the corresponding 21-hydroxy steroids. The steroidal alcohol is contacted with the appropriate acid of the formula ##STR11## in the presence of a suitable dehydrating agent (e.g. dicyclohexylcarbodiimide). Alternatively, the acid chloride or acid anhydride corresponding to the acid of formula [II], [III] or [IV] can be reacted with the steroidal alcohol.

When the steroidal starting material employed in the procedure described above is a 17α,21-dihydroxy compound, the resultant 17α-hydroxy, 21-ester can be treated with cuprous iodide, methyl lithium and N,N,N',N'-tetramethylenediamine tetrachlorocuprate according to the procedure of G. H. Phillips, B. M. Bain and G. Durrant as described in U.S. Pat. No. 3,891,631 [Chem. Abstr., 81, 4142 (1974)], to effect transfer of the ester group from the 21- to the 17-position, affording the corresponding 21-hydroxy, 17α-ester. That product can then be subjected to the hereinabove-described esterification process once again, to afford the 17α,21-diesters wherein the ester groups can be the same or different.

In order to still further illustrate the invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative.

EXAMPLE 1 Illustrative Preparation of Starting Materials [a] N,N-Diethyl-3-oxaglutaramic acid

To a suspension of diglycolic dianhydride (11.02 g, 0.095 mole) in 50 ml dichloromethane was added dropwise, with cooling so that a temperature was maintained between 22-25 C., diethylamine (7.13 g, 0.0975 mole). The reaction was then stirred at room temperature 1 hour. The light yellow solution was concentrated in vacuo to an oil which, after an unsuccessful crystallization attempt, was reconcentrated under strong vacuum to give 13 g (79% yield) of the desired compound as a light golden oil. NMR (CDCl3) δ13.57 ##STR12## 4.43 ##STR13## 3.35 (m, 4, --N(CH2 CH3)2), 1.14 (m, 6, --N(CH2 CH3)2); IR (Neat) 1730 cm-1 (s, HO--C═O), 1620 cm-1 (s, >N--C═O).

The remaining amides were prepared in a similar fashion to give the following compounds:

[b] N,N-(N'-Methyl-3'-azapentamethylene)succinamic acid

Analytical sample of yellow crystals from THF-Et2 O; mp 122-127 C.; NMR (D2 O) δ3.87 (s, 4, O═C--N CH2 --), 3.33 (s, 4, CH3 --N CH2), 2.90 (s, 3, >NCH3), 2.57 (m, ##STR14## IR (KBr) 1630 cm-1 ##STR15## 1600 cm-1 (s, >N--C═O);

Anal. Calcd for C9 H16 N2 O3 : C, 53.98; H, 8.05; N, 13.99. Found: C, 53.72; H, 8.08; N, 13.78.

[c] N,N-(3'-Oxapentamethylene)succinamic acid

Analytical sample of clear, colorless crystals from THF-Et2 O; mp 73-78 C.; NMR (D2 O) δ3.67 (s, 8, N--CH2 CH2 --O), 2.68 ##STR16## IR (KBr) 1730 cm-1 ##STR17## 1605 cm-1 ##STR18##

Anal. Calcd for C8 H13 NO4 : C, 51.32; H, 7.00; N, 7.48. Found: C, 51.54; H, 7.12; N, 7.35.

[d] N,N-Dipropylsuccinamic acid

Analytical sample of clear, colorless crystals from CH2 Cl2 ; mp 35-37 C.; NMR (CDCl3) δ11.51 (m, 1, --OH), 3.28 (t, 4, NCH2), 2.65 (s, 4, OC(CH2)2 CO), 1.62 (m, 4, NCH2 CH2), 0.94 (m, 6, N(CH2 CH2 CH3)2); IR (NaCl) 1725 cm-1 (s) (O--C═O); 1630 cm-1 and 1600 cm-1 (s) (N--C═O).

Anal. Calcd for C10 H19 NO3 : C, 59.67; H, 9.52; N, 6.96. Found: C, 59.42; H, 9.59; N, 6.97.

[e] N,N-Tetramethylenesuccinamic acid

Yellow crystals mp 103-108 C. from CH2 Cl2 -ether (75:200) in 87% yield; NMR (CDCl3) δ11.8-11.1 (m, 1, OH), 3.7-3.3 (m, 4, CH2 --N), 2.63 (s, 4, O═C--CH2 CH2 C═O) and 2.25-1.6 (m, 4, CH2 --CH2 N).

Anal. Calcd for C8 H13 NO3 : C, 56.12; H, 7.65; N, 8.18. Found: C, 55.88; H, 7.52; N, 8.05.

[f] N,N-Diethylsuccinamic acid

Yellow crystals mp 80.5-86 C. from CH2 Cl2 -heptane in 88% yield; NMR (CDCl3) δ10.9-10.1 (m, s, OH), 3.6-3.1 (m, 4, N--CH2 CH3), 2.67 (s, 4, O═C--CH2 --CH2 C═O) and 1.5-0.9 (m, 6, CH3 --CH2 N).

Anal. Calcd for C8 H15 NO3 : C, 55.47; H, 8.73; N, 8.09. Found: C, 55.62; H, 8.83; N, 8.03.

The crude products above were used in subsequent reactions. Small amounts of material were recrystallized for the analytical data.

[g] N,N-Dimethylsuccinamic acid

N,N-dimethylsuccinamic acid was prepared in a somewhat different manner than the other amides. Since 40% dimethylamine in water was used as the amine source, the water had to be removed by evaporation at 60 C. (0.1 mm). The oily residue that remained was dissolved in CH2 Cl2 and the CH2 Cl2 solution was dried over Na2 SO4. The CH2 Cl2 solution (135 ml) was diluted first with 75 ml of ether, which caused an oil to form. The precipitate (4.1 g, mp 137-147 C.) was not the desired compound (NMR) and was discarded. The filtrate was concentrated in vacuo to give a white solid (16.7 g) which was crystallized from hot THF to give the desired compound: 11.7 g, 47% yield; mp 86-89; NMR (CDCl3) δ11.3 (s, 1, OH), 3.05 and 2.96 (two s, 6, CH3 --N) and 2.67 (s, 4, O═C--CH2 CH2 --C═O).

Anal. Calcd. for C6 H11 NO3 : C, 49.64; H, 7.64; N, 9.65. Found: C, 50.00; H, 7.83; N, 9.70.

EXAMPLE 2 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione

Hydrocortisone (14.6 g, 0.04 mole) was added to 50 ml of pyridine to give a clear yellow solution. Immediately, 6.92 g (0.04 mole) of N,N-diethylsuccinamic acid and 8.30 g (0.04 mole) of dicyclohexylcarbodiimide were added to the solution. As the clear solution became thick with precipitate, CH2 Cl2 (100 ml) was added. The suspension was stirred overnight at room temperature. The suspension was then filtered and the filtrate was concentrated in vacuo to give a gum. The gum was triturated with 100 ml of THF. The resulting suspension was filtered and the filtrate was concentrated again. The residue from the concentration was then crystallized from THF-ether (50:25) initially but every hour or so an additional 100 ml of ether was added. The crystals that formed were filtered and dried to give 16.5 g of the desired compound as its etherate. A subsequent recrystallization from THF-ether as above gave 13.2 g (mp 100-105 C., 64% yield) of the succinamate ester: TLC (silica gel, acetone) Rf 0.37; IR (KBr) 3500-3400 cm-1 (m) (OH) and 1735, 1715, 1645 and 1620 cm-1 (s) (C═O); NMR (CDCl3) δ5.65 (s, 1, O═C--CH═C), 4.93 (s, 2, O═C--CH2 --OC═O), 4.6-4.3 (m, 1, CH--OH), 3.33 (q, J=7 Hz, 4, NCH2 CH3), 2.7 (m, 4, O═CCH2 --CH2 --C═O), 1.18 (t, J=7 Hz, 6, NCH2 CH3), 1.45 (s, 3, CH3 --C), 0.97 (s, 3, CH3 --C) and 3.1-0.8 (m, 23, CH2 and CH and 2, OH); [α]23.5 D+139 (C=0.55, ethanol).

Anal. Calcd for C29 H43 NO7 : C, 67.28; H, 8.56; N, 2.70. Found: C, 67.55; H, 8.75; N, 2.65.

EXAMPLE 3 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione

To 3.62 g (0.01 mole) of hydrocortisone dissolved in pyridine (14 ml) was quickly added 1.45 g (0.01 mole) of N,N-dimethylsuccinamic acid and 2.10 g (0.01 mole) of dicyclohexylcarbodiimide. The thick precipitate that formed was diluted with 28 ml of CH2 Cl2 and the suspension was allowed to stir overnight at room temperature. The dicyclohexylurea was filtered and the filtrate was concentrated to give a pale greenish solid which was redissolved in CH2 Cl2 ; that suspension was filtered. The CH2 Cl2 filtrate was concentrated in vacuo to give a foam. The foam was crystallized from THF-ether to give 3.12 g of crystals which contained hydrocortisone by TLC. The crystals were recrystallized from THF (10 ml) to give 1.73 g (35% yield) of the desired product in analytically pure form; mp 228-233 C.; TLC (silica gel, ether-methanol, 10:3), Rf 0.5, IR (KBr) 3420 cm-1 (s) (OH) 1735, 1720, 1655 and 1630 cm-1 (s) (C═O); NMR (CDCl3) δ 5.7 (s, 1, O═C--CH═C), 4.97 (s, 2, O═C--CH2 O2 C), 4.55-4.35 (m, 1, CH--OH), 3.2 and 3.1 (two s, 6, N--CH3), 2.7 (m, 4, O--CCH2 CH2 C═O), 1.45 (s, 3, CH3 --C), 0.97 s, 3, CH3 --C) and 3.2-0.7 (m, 23, CH2 and CH and 2, OH); [α]25 D+137 (C=0.5, dioxane).

Anal. Calcd C27 H39 NO7 : C, 66.23; H, 8.03; N, 2.86. Found: C, 66.41; H, 8.35; N, 2.68.

EXAMPLE 4 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione

To 3.62 g (0.01 mole) of hydrocortisone dissolved in pyridine (14 ml) was quickly added 1.71 g (0.01) mole of N,N-tetramethylenesuccinamic acid and 2.10 g (0.01 mole) of dicyclohexylcarbodiimide. The thick precipitate that formed was diluted with 28 ml of CH2 Cl2 and the suspension was allowed to stir overnight at room temperature. The dicyclohexylurea was filtered and the filtrate was concentrated in vacuo to give a green gum. The gum was suspended in CH2 Cl2 (60 ml) and the suspension was filtered to give 2.5 g of an off-white solid. The white solid contained hydrocortisone by TLC. The solid was crystallized from 20 ml of boiling THF to give 1.94 g (mp 148-154 C., 37% yield) of the desired ester as white crystals which were one spot upon TLC (silica gel, ether-methanol 10:3) Rf 0.53. An analytically pure sample was obtained by further crystallization from THF: mp 152-155 C.; IR (KBr) broad band from 3500-3300 cm-1 (s) (OH) and 1720, 1700, 1660 and 1610 cm-1, (s) (C═O); NMR (CDCl3) δ 5.63 (s, 1, O═C--CH═C), 4.93 (s, 2, O═C--CH2 O2 C), 4.55-4.35 (m, 1, CH--OH) 3.5-3.2 (m, 4, CH2 N), 2.7-2.55 (m, 4, O═C--CH2 CH2 --C═O), 1.43 (s, 3, CH3 --C), 0.93 (s, 3, CH3 --C) and 3.1-0.8 (m, 27, CH2 and CH and 2, OH); [α]25 D+116 (C=0.47, dioxane).

Anal. Calcd for C29 H41 NO7.1.5 H2 O: C, 64.18; H, 8.17; N, 2.58. Found: C, 62.24; H, 7.94; N, 2.21.

EXAMPLE 5 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione

To a solution of hydrocortisone (10 g, 0.028 mole) and N,N-(3'-oxapentamethylene)succinamic acid (5.16 g, 0.028 mole) in 50 ml pyridine was added dicyclohexylcarbodiimide (5.67 g, 0.028 mole). After the reaction was stirred 10 minutes, 50 ml CH2 Cl2 was added to it to keep the suspension, which had formed, sufficiently fluid for stirring. The reaction was stirred overnight then filtered to give a residue of dicyclohexylurea which weighed 4.51 g (83% yield) and a filtrate which was concentrated in vacuo to a light off-white foam. The foam was in turn triturated (25 ml CH2 Cl2, 3 hours) then filtered to give a residue weighing 6.4 g and a filtrate which was concentrated in vacuo to 10.4 g. The 10.4 g was in turn triturated (100 ml MeOH, overnight) then filtered to give a residue weighing 4.3 g. The residue was recrystallized from 200 ml EtOH to give a fine white crystalline product, which, after it was dried in vacuo (35 C., 2 hours), weighed 3.4 g: mp 223-225 C.; NMR (DMSO-d6) δ5.55 (s, 1, O═C--CH═), 5.33 (s, 1, OH), 4.93 (ABq, 2, JAB=19 Hz, Δ.sub.νAB =19 Hz, O═C--CH2 --O), 4.28 (m, 2, CHOH), 3.50 (m, 8, N(CH2 CH2)2 O), 2.62 (s, 4, OCCH2 CH2 CO), 1.38 (s, 3, C--CH3), 0.78 (s, 3, C--CH3), 2.9-0.8 (m, 17, CH, CH2- ; IR (KBr) 3500-3300 cm-1 (s) (OH), 1710, 1660 and 1610 cm-1 (s) (C═O); [α]25 D=+131, (C=0.5, dioxane); TLC (silica gel), 10% MeOH/Et2 O) Rf 0.29.

Anal. Calcd for C29 H41 NO8 : C, 65.51; H, 7.77; N, 2.64. Found: C, 65.46; H, 7.99; N, 2.21.

EXAMPLE 6 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(N,N-diethyl-3'-oxaglutaramyloxy)-3,20-dione

To a solution of hydrocortisone (5.12 g, 0.014 mole) and N,N-diethyl-3-oxaglutaramic acid (2.57 g, 0.015 mole) in 15 ml pyridine was added dicyclohexylcarbodiimide (3.06 g, 0.015 mole). After the reaction was stirred 10 minutes, 25 ml CH2 CH2 was added to it to keep the suspension which had formed sufficiently fluid for stirring. The reaction was stirred overnight at room temperature then filtered. The residue was washed twice with CH2 Cl2 and dried to give 2.6 g (89% yield) dicyclohexylurea. The filtrate was concentrated in vacuo to give a foam which was suspended in 20 ml hot dichloromethane and allowed to cool. The suspension was filtered and the filtrate was concentrated in vacuo to give a residue which was dissolved in 20 ml THF; the solution was then diluted to 100 ml with Et2 O. Crystals formed overnight and were filtered to give 2.69 g of product which TLC showed to be contaminated with hydrocortisone. These crystals were in turn recrystallized from THF-Et2 O (20:80). After 5 days, 2.14 g (29% yield) of light brown needles were filtered which were the etherate of the desired product: mp 95-97.5 C., NMR (CDCl3) δ5.67 (s, 1, O═C--CH═), 5.07 (s, 2, O═C--CH2 O--C═O), 4.48 (m, 3, CHOH,--OH), 4.35 (s, 2, --OCOCH2 O--), 4.30 (s, 2, NCOCH2 O--), 3.48 (q, 4, O(CH2 CH3)2, J=5 Hz), 3.34 (m, 4, N(CH2 CH3)2), 1.44 (s, 3, C--CH3), 1.18 (t, 6, O(CH2 CH3)2, J=5 Hz), 0.93 (s, 3, C--CH3), 2.9-0.9 (m, 23, CH, CH2); IR (KBr) 3400 cm-1 (s) OH and 1730, 1710 and 1640 cm-1 (s) (C═O); TLC (silica gel, 10% MeOH/Et2 O) Rf 0.36; [α]23 D=+117 (C=0.5, dioxane).

Anal. Calcd for C29 H43 NO8.C4 H10 O: C, 65.21; H, 8.79; N, 2.30. Found: C, 65.15; H, 8.60; N, 2.06.

EXAMPLE 7 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(N,N-dipropylsuccinamyloxy)-3,20-dione

To a solution of hydrocortisone (5 g, 0.014 mole) and N,N-di-n-propylsuccinamic acid (2.78 g, 0.014 mole) in 25 ml pyridine at room temperature was added dicyclohexylcarbodiimide (2.85 g, 0.014 mole). After the reaction was stirred 10 minutes, 25 ml dichloromethane was added to it to keep the suspension which had formed sufficiently fluid for stirring. After the reaction was stirred overnight, it was filtered. The residue was washed twice with CH2 Cl2 and dried in the air to give 2.46 g (91% yield) dicyclohexylurea. The filtrate was concentrated in vacuo to a residue which was dissolved in 25 ml hot THF. After the THF solution was filtered while hot, the resulting filtrate was diluted to 150 ml with Et2 O. The product crystallized overnight and was filtered and dried to give 3.49 g of light brown crystals, which a preliminary NMR showed to be contaminated with solvent. The crystals were dried in vacuo (50 C., 2 hours) to give 2.81 g (37% yield) of the desired product: mp 157-162 C.; NMR (CDCl3) δ5.64 (s, 1, O═C-CH═), 4.98 (m, 2, O═C-CH2 O), 4.46 (m, 1, CHOH), 3.8-4.2 (m, 2, OH), 3.24 (t, 4, J=7 Hz, N CH2), 2.70 (s, 4, OCCH2 CH2 CO), 1.46 (s, 3, C-CH3), 0.96 (s, 3, C-CH3), 0.94 (m, 6, N(CH2 CH2 CH3)2), 2.9-0.8 (m, 21, CH, CH2); TLC (silica gel, 10% MeOH/Et2 O) Rf 0.56; [α]25 D=+127 (C=0.5, dioxane); IR (KBr) 3400 cm-1 (s) (OH), 1730, 1710, 1640 and 1610 cm-1 (s) (C═O).

Anal. Calcd for C31 H47 NO7 : C, 68.23; H, 8.68; N, 2.57. Found: C, 68.48; H, 9.02; N, 2.13.

EXAMPLE 8 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione

To a solution of hydrocortisone (3.62 g, 0.01 mole) and N,N-(N'-methyl-3'-azapentamethylene)succinamic acid (2.00 g, 0.01 mole) in 15 ml pyridine at room temperature was added dicyclohexylcarbodiimide (2.00 g, 0.01 mole). After stirring the reaction mixture 10 minutes, 25 ml dichloromethane was added to it to keep the suspension, which had resulted, sufficiently fluid for stirring. After stirring overnight, the reaction was filtered. The residue was washed twice with CH2 Cl2 and air dried to give 1.65 g (84% yield) dicyclohexylurea. The filtrate was concentrated in vacuo to give a light brown foam which was in turn triturated 2 hours with 10 ml CH2 Cl2 to give a suspension which was filtered. The residue was dried in the vacuum oven 3 hours at 40 C. after a preliminary NMR showed contamination of the product with CH2 Cl2. The resulting finely crystalline, off-white powder was the desired product: 2.70 g, 51% yield; mp 159-163 C.; NMR (DMSO-d6) δ5.53 (s, 1, O═C-CH═C-), 5.32 (m, 1, C-OH), 4.91 (ABq, 2, JAB=17 Hz, Δ.sub.νAB =18 Hz, O═C-CH2 -O), 4.29 (m, 2, CH-OH), 3.41 (m, 8, -N(CH2 CH2)N-), 2.59 (s, 3, N-CH3), 1.37 (s, 3, C-CH3), 0.78 (s, 3, C-CH3), 2.7-0.8 (m, 21, CH, CH2); IR (KBr) 3400 cm-1 (s) (OH), 1730 cm-1 and 1710 cm-1 (s) (C-C═O and O-C═O) and 1640 and 1615 cm-1 (s) (O═C-CH═C, N-C═O); [α]24 D=+122 (C=0.5, dioxane); TLC (silica gel, MeOH) Rf 0.27.

Anal. Calcd for C30 H44 N2 O7 : C, 66.15; H, 8.14; N, 5.14. Found: C, 66.22; H, 8.21; N, 5.04.

EXAMPLE 9 Preparation of 4-Pregnene-11β-Hydroxy-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione

To 8.64 g (0.02 mole) of hydrocortisone 17-butyrate dissolved in 25 ml of pyridine was added a mixture of 4.4 g (0.021 mole) of dicyclohexylcarbodiimide and 3.46 g (0.02 mole) of N,N-diethylsuccinamic acid. After 4 minutes, 50 ml of dichloromethane was added to the clear solution. After 4 hours, the precipitate that had formed was filtered and washed with 100 ml of dichloromethane. The filtrate was concentrated in vacuo to gum which was chromatographed on Silic AR CC-7 (500 g) using ether as the eluent to give three fractions.

The first fraction was crystallized from methanol to give 272 mg (mp 180-190 C., 3% yield) of hydrocortisone 21-butyrate.

The second fraction was crystallized from methanol to give 825 mg (mp 211-214 C., 9.5% recovery) of hydrocortisone 17-butyrate.

The third fraction was crystallized from dichloromethaneheptane 60:360 to give 5.28 g (mp 81-83, 44% yield) of the desired hydrocortisone 17-butyrate 21-(N,N-diethylsuccinamate): TLC (silica gel, ether) developed twice, Rf 0.25; IR (KBr) 3460-3360 cm-1 (m) (OH) 1720 cm-1 (s) (C═O) and 1640, 1630 and 1615 cm-1 (s) (C═O); NMR (CDCl3) δ5.65 (s, 1, O═C-CH═C), 4.65 (AB quartet, 2, J=14 Hz, Δ.sub.νAB =33 Hz, O-CH2 -C═O), 4.47 (broad m, 1, CH-OH), 3.30 (q, 4, J=8 Hz, CH3 CH2 N), 2.60 (broad s, 4, O═C-CH2 CH2 C═O), 1.37 (s, 3, CH3 -C) and 3.0-0.7 (m, 33, CH3, CH2 and CH and 1, OH); [α ]26.5 D+67, (C=0.5, dioxane).

Anal. Calcd for C33 H49 NO8.0.5 H2 O; C, 66.41; H, 8.44; N, 2.34. Found: C, 66.76; H, 8.56; N, 2.00.

EXAMPLE 10 Preparation of 4-Pregnene-11β-hydroxy-17α-butyryloxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione

A mixture of 2.16 g (0.005 mole) of hydrocortisone 17-butyrate, 0.65 g (0.005 mole) of L-2-pyrrolidone-5-carboxylic acid and 1.05 g (0.005 mole) of dicyclohexylcarbodiimide was partially dissolved in CH2 Cl2 (50 ml) to which 1 ml of pyridine was added. The resulting suspension was allowed to react overnight. Then the dicyclohexylurea was filtered and the filtrate was concentrated in vacuo to a gum which was triturated with ether to remove some of the unreacted hydrocortisone 17-butyrate. The ether solution was adsorbed onto and chromatographed on silicAR CC-7 using first ether and then acetone to give two fractions. The first fraction that was eluted with ether was hydrocortisone 17-butyrate and it was discarded. The second acetone soluble fraction was the desired compound: 1.32 g, 49% yield; foamed at 85 C.; IR (KBr) 3420-3360 cm-1 (m) (OH) and 1750-1650 cm-1 (broad s) (C═O); NMR (CDCl3) δ6.83 (broad s, 1, N-H), 5.7 (s, 1, O═C-CH═C) 4.9 (AB quartet, J=16 Hz, Δ.sub.νAB =18 Hz, 2, O═C-CH2 -O-C═O), 4.6-4.2 (m, 2, O2 C-CH-N and CH-OH), 1.45 (s, 3, CH3 -C), 1.0 (s, 3, CH3 -C) and 3.2-0.8 (m, 27, CH2 and CH and 2, OH); [α]27 D+49 (C=0.5, dioxane).

Anal. Calcd for C30 H41 NO8 : C, 66.28; H, 7.60; N, 2.58. Found: C, 65.86; H, 7.70; N, 2.96.

EXAMPLE 11 Preparation of 4-Pregnene-11β,17α-dihydroxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione

A mixture of 21.6 g (0.06 mole) of hydrocortisone, 7.8 g (0.06 mole) of L-2-pyrrolidone-5-carboxylic acid and 12.6 g (0.06 mole) of dicyclohexylcarbodiimide was dissolved in 40 ml of pyridine. A vigorous reaction resulted which caused the solution to solidify. The solid was suspended in 375 ml of CH2 Cl2 overnight, then filtered. The filtrate was concentrated in vacuo to a foam which was redissolved in 50 ml of CH2 Cl2 and filtered. The CH2 Cl2 solution was diluted with 600 ml of ether. The gummy solid suspension that resulted gradually became a fine white powder after the suspension was stirred for 2 hours. The suspension was then filtered and dried in vacuo at 60 for 10 hours to give 22.1 g (mp 140-142 C., 77% yield) of the desired compound: TLC (silica gel, acetone) Rf 0.46; IR (KBr) 3400 cm-1 (m) (broad OH and NH) and 1650 cm-1 (s) (broad C═O); NMR (CDCl3) δ6.67 (s, 1, N-H), 5.63 (s, 1, O═C-CH═C), 5.03 (broad s, 2, O═C-CH2 -O), 4.6-4.3 (m, 2, CH-OH and O2 C-CH-N), 1.43 (s, 3, CH3 -CO), 0.90 (s, 3, CH3 -C) and 3.2-0.7 (m, 21, CH2, CH, 2, OH); [α]27 C+131 (C=1.0, methanol).

Anal. Calcd for C26 H35 NO7 : C, 65.94; H, 7.45; N, 2.96. Found: C, 65.47; H, 7.54; N, 3.37.

EXAMPLE 12 Preparation of 1,4-Pregnadiene-17α-hydroxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione

To 3.58 g (0.01 mole) of prednisone partially dissolved in 10 ml of pyridine was added 1.73 g (0.01 mole) of N,N-diethylsuccinamic acid and 2.06 g (0.01 mole) of dicyclohexylcarbodiimide. After 1 hour, CH2 Cl2 (10 ml) was added and after 3 hours, the suspension that resulted was filtered. The filtrate was concentrated in vacuo to give a foam which was dissolved in 15 ml of THF. The THF solution was filtered and warmed to boiling, then diluted with ether until the solution was nearly cloudy. The solution was allowed to cool overnight. The crystals were filtered to give 3.70 g (mp 186-197 C., 72% yield) of the desired compound in a crude form. These crystals were purified by recrystallization from 10 ml of THF to give 2.40 g (mp 204-206 C., 47% yield) of the pure ester: IR (KBr) 3400 cm-1 (m) (OH) 1730, 1715, 1695, 1655, 1625 and 1613 cm-1 (s) (C═O); NMR (CDCl3) δ6.95 (AX quartet, 2, JAX=10 Hz, Δ.sub.νAX =91 Hz, O═C-CH═CH), 6.07 (s, 1, O═C-CH═C), 4.90 (AB quartet, 2, J=18 Hz, Δ.sub.νAB =21.5 Hz, O═C-CH2 -O), 4.67 (s, 1, OH), 1.47 (s, 3, CH3 -C), 0.67 (s, 3, CH3 -C) and 3.8-1.0 (m, 27, CH3, CH2 and CH); [α]24 D+144.5 (C=0.55, dioxane).

Anal. Calcd for C29 H39 NO7 : C, 67.81; H, 7.65; N, 2.73. Found: C, 68.15; H, 7.80; N, 2.40.

EXAMPLE 13 Preparation of 1,4-Pregnadiene-11β,17α-dihydroxy-9α-fluoro-16α-methyl-21-(N,N-diethylsuccinamyloxy)-3,20-dione

To 3.90 g (0.01 mole) of 1,4-pregnadiene-11β,17α,21-trihydroxy-9α-fluoro-16α-methyl-3,20-dione (dexamethasone) dissolved in 10 ml of pyridine was added 1.73 g (0.01 mole) of N,N-diethylsuccinamic acid and 2.06 g (0.01 mole) of dicyclohexylcarbodiimide. The solution that resulted quickly became a thick suspension which was diluted with 10 ml of CH2 Cl2. After 3 hours, the suspension was filtered and the filtrate was concentrated in vacuo to give a foam. The foam was dissolved in 30 ml of hot THF and filtered. The filtrate was diluted with ether until it nearly turned cloudy, then it was allowed to cool overnight. The crystals were filtered to give 3.68 g (mp 195-226 C., 67% yield) of the crude product contaminated with dexamethasone. The crude product was recrystallized from THF (10 ml) to give 2.30 g (mp 202-204 C., 42% yield) of the desired ester: IR (KBr) 3400 cm-1 (m) (OH) and 1730, 1710, 1650 and 1610 cm-1 (s) (C═O); NMR (CDCl3) δ6.80 (AX quartet, 2, Jax =10 Hz, Δ.sub.νAX =61 Hz, O═C-CH═CH), 6.1 (s, 1, O═C-CH═C), 4.93 (broad s, 1, O═C-CH2 -O), 4.55-4.1 (m, 1, CH-OH), 1.57 (s, 3, CH3 -C), 1.05 (s, 3, CH3 -C) and 3.9-0.8 (m, 34, CH3, CH2, CH, 2, OH); [α]24 D+68 (C=0.5, dioxane).

Anal. Calcd for C30 H42 NO7 : C, 65.79; H, 7.73; N, 2.56. Found: C, 68.15; H, 7.80; N, 2.40.

EXAMPLE 14 Preparation of 4-Pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione

To a suspension of 0.456 g (0.0024 mole) of cuprous iodide in 20 ml of dry THF at 0 C. was added 2.66 ml of 1.6 M methyl lithium (0.0043 mole) in ether. The reaction mixture was stirred at 0 C. for 15 minutes, then the temperature was reduced to -30 C. and 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione (0.50 g, 0.00096 mole) was added. The reaction was stirred at -25 C. for 45 minutes then 1.53 g of N,N,N',N'-tetramethylenediamine tetrachlorocuprate was added and the reaction mixture was allowed to warm to room temperature. The mixture was stirred overnight at room temperature, then was poured into 150 ml of 3 M NH4 Cl and stirred for one hour. The oily precipitate was extracted with ethyl acetate and chromatographed on silicAR CC-7 using methanol-ether 10:90 as the eluent to give crystals (0.12 g, mp 160 -170 C., from methanol) of the desired product: IR (KBr) 3460 cm-1 (s) (O-H), 1720, 1705 (sh), 1660, 1625 and 1610 (sh) cm-1 (s) (C═O); NMR (CDCl3) δ5.66 (m, 1, O═C-CH═C), 4.6-4.3 (m, 1, CH-OH), 4.27 (s, 2, O═CCH2 -OH), 3.5-3.1 (m, 4, NCH2 CH3), 2.60 (sharp m, 4, O═CCH2 CH2 C═O), 1.61 (s, 3, CH3 -C), 0.95 (s, 3, CH3 -C), 1.17 (t, J=6 Hz, 6, N-CH2 CH3), 3.0-0.8 (m, 19, CH2, CH and OH).

Anal. Calcd for C29 H43 NO7.H2 O: C, 65.02; H, 8.46; N, 2.61. Found: C, 64.96; H, 8.30; N, 2.58.

Substitution of an equivalent quantity of 4-pregnene-11β,17α-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione for the 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione used above and substantial repetition of the foregoing procedure afforded 4-pregnene-11β,21-dihydroxy-17α-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione.

EXAMPLE 15

The procedure of Example 9 was repeated, except that an equivalent quantity of 4-pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione was used in place of the hydrocortisone 17-butyrate. There was thus obtained 4-pregnene-11β-hydroxy-17α,21-bis(N,N-diethylsuccinamyloxy)-3,20-dione.

Similarly, use of an equivalent amount of 4-pregnene-11β,21-dihydroxy-17α-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione as the steroidal starting material in the procedure of Example 9 afforded 4-pregnene-11β-hydroxy-21-(N,N-diethylsuccinamyloxy)-17α-[N,N-(N'-methyl-3'-azapentamethylene)-succinamyloxy]-3,20-dione.

EXAMPLE 16

Following those procedures and methods outlined in the foregoing Examples 1 to 15, but merely by substituting the appropriate specific reactants, the following additional compounds according to the invention are prepared: 4-pregnene-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione; 4-pregnene-11β-hydroxy-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; 4-pregnene-11β-hydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylglutaramyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione; 4-pregnene-11β,17α-dihydroxy-21-(N,N-diethylsebacamyloxy)-3,20-dione; 4-pregnene-11β,21-dihydroxy-17α-(N,N-dimethylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,21-dihydroxy-17α-(N,N-diethylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione; 4-pregnene-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione; 4-pregnene-17α-hydroxy-21-(N,N-dioctylsuccinamyloxy)-3,11,20-trione; 4-pregnene-17α-hydroxy-21-(N,N-tetramethylenesuccinamyloxy)-3,11,20-trione; 4-pregnene-17α-hydroxy-21-(N,N-pentamethylenesuccinamyloxy)-3,11,20-trione; 1,4-pregnadiene-11β,17α-dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione; 1,4-pregnadiene-11β,17α -dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)-succinamyloxy]-3,20-dione; 1,4-pregnadiene-11β,17α-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-17α-hydroxy-21-(2'-oxopyrrolidin-5'-yl)-carbonyloxy-3,11,20-trione; 1,4-pregnadiene-17α-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione; 1,4-pregnadiene-17α-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,11,20-trione; 1,4-pregnadiene-9α-fluoro-11β,16α-dihydroxy-17α-valeryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethylglutaramyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β,16α,17α-trihydroxy-21-(N,N-diethyladipamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dimethylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dipropylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β,17α-dihydroxy-16α-methyl-21-(N,N-diethylsebacamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-dimethylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β,21-dihydroxy-16α-methyl-17.alpha.-(N,N-diethylsuccinamyloxy)-3,20-dione; 4-pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dipropylsuccinamyloxy)-3,20-dione; 4-pregnene-9α-fluoro-11β,21-dihydroxy-17α-(N,N-dibutylsuccinamyloxy)-3,20-dione; 4-pregnene-9α-fluoro-11β,17α-dihydroxy-21-(N,N-dibutylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-dioctylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-tetramethylenesuccinamyloxy)-3,20-dione; 1,4-pregnadiene-11β-hydroxy-16α,17α-isopropylidenedioxy-21-(N,N-pentamethylenesuccinamyloxy)-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha. -dihydroxy-21-[N,N-(3'-oxapentamethylene)succinamyloxy]-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-[N,N-(N'-methyl-3'-azapentamethylene)succinamyloxy]-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-16α-methyl-11β,17.alpha.-dihydroxy-21-(N,N-dibenzylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(2'-oxopyrrolidin-5'-yl)carbonyloxy-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethylglutaramyloxy)-3,20-dione; 1,4-pregnadiene-6α,9α-difluoro-11β-hydroxy-16α,17.alpha.-isopropylidenedioxy-21-(N,N-diethyladipamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; 1,4-pregnadiene-9α-fluoro-11α-hydroxy-16β-methyl-17.alpha.-acetyloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione; and 1,4-pregnadiene-9α-fluoro-11β-hydroxy-16α-methyl-17.alpha.-butyryloxy-21-(N,N-diethylsuccinamyloxy)-3,20-dione.

EXAMPLE 17 Effect of Selected Steroid Derivatives on Skin Thickness

A modification of the method of Smith et al, Arch Derrmatol, 112, 1115 (1976), was used. Hairless mice were used instead of rats. The steroids were tested at 0.03 M in propyleneglycol suspension except for hydrocortisone 17-butyrate which was soluble. Each suspension (50 μl) was applied to the backs of 9 mice daily. On the twenty-ninth day of the experiment, the mice were sacrificed with carbon dioxide and the double fold skin thickness was immediately measured using an Ames micrometer accurate to 0.0001 inch at a pressure of 28 lb/cm2. The measurement was taken after three minutes had elapsed from the time the mouse skin was placed in the micrometer. The results are shown in Table I:

              TABLE I______________________________________                 % Decrease from                 Control______________________________________Control (propylene glycol)Hydrocortisone 21-acetate                   37.5Hydrocortisone 21-(N,N-diethylsuccinamate)                   26.7Hydrocortisone 17-butyrate                   39.2Triamcinolone acetonide 45.8______________________________________
EXAMPLE 18 Effect of Selected Steroid Derivatives on Ear Burn Inflammation

A modification of the method of Tonelli et al, Endocrinology, 77, 625 (1965), was used. Sprague-Dawley rats were used which had a weight of 555 gm. The rats were first anesthetized with phenobarbitol, then the right ear of each rat was burned on both side for 10 seconds between two vertically oriented brass cylinders heated with water at 51.7 C. from a constant temperature bath. The pressure of the cylinder on the rat ear was reproduced by using only the weight of the top brass cylinder (2.5 lbs) to apply the pressure. The burned rat ear was then immediately treated on both sides with 50 ml of vehicle (isopropyl myristate) or 0.03 M steroid in the vehicle. After 16 hours, both ears of the rat were removed along anatomical guidelines and weighed.

The increase of weight caused by the burn was determined by subtracting the weight of the untreated left ear from the weight of the treated right ear.

The percent inhibition of inflammation was then determined as the weight increase of burned rat ears treated only with vehicle minus the weight increase of burned rat ears treated with vehicle containing the steroid divided by the weight increase of burned rat ears treated only with vehicle times one hundred. The results for 5 rats are shown in Table II:

              TABLE II______________________________________                 % Inhibition______________________________________Hydrocortisone          3.3Hydrocortisone 21-acetate                   31.0Hydrocortisone 21-(N,N-diethylsuccinamate)                   49.2Hydrocortisone 17-butyrate                   28.9Triamcinolone acetonide 53.8Hydrocortisone 21-(2'-oxopyrrolidin-5'-yl)carboxylate          50.5Hydrocortisone 21-(N,N-diethylsuccinamate)17-butyrate             20.4______________________________________
EXAMPLE 19 Effect of Selected Steroid Derivatives on Thymus Weight

The rats used in the ear burn test described in Example 18 were revived and 48 hours after the burn and application of the steroid, they were sacrificed with carbon dioxide. Then their thymus glands were removed and weighed. The results are shown in Table III. The lower the weight of thymus, the more pronounced the systemic effect of the steroid. There was no significant difference in the relative toxicity of the steroids when the steroid was applied to unanesthetized rats which did not have their ears burned and removed.

              TABLE III______________________________________                Thymus Weight (mg)______________________________________Control                233.5  11.5Hydrocortisone         190.3  29.7Hydrocortisone 21-acetate                  177.2  11.0Hydrocortisone 21-(N,N-diethyl-                  215.7  20.1 succinamate)Hydrocortisone 17-butyrate                  149.6  11.7Triamcinolone acetonide                  65.3  8.1Hydrocortisone 21-(2'-oxopyrrolidin- 5'-yl)carboxylate     151.9  7.0Hydrocortisone 21-(N,N-diethyl- succinamate)17-butyrate                  176.8  7.6______________________________________

The compounds of the present invention are conveniently administered to warm-blooded animals via conventional oral or topical administration with any suitable nontoxic pharmaceutically acceptable oral or topical inert carrier material. Such carrier materials are well-known to those skilled in the art of oral and topical pharmaceutical formulations. For those not skilled in the art, reference is made to the text entitled REMINGTON'S PHARMACEUTICAL SCIENCES, (Fourteenth Edition), 1970. In a typical preparation for oral administration, e.g., tablet or capsule, any one of the compounds of the instant invention is combined in an anti-inflammatory effective amount with any oral nontoxic pharmaceutically acceptable inert carrier such as lactose, starch (pharmaceutical grade), dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar. Additionally, when required, suitable binders, lubricants, disintegrating agents and coloring agents can also be included. Typical binders include starch, gelatin, sugars such as sucrose, molasses and lactose, natural and synthetic gums such as acacia, sodium alginate, extract of Irish moss, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polyethylene glycol, ethylcellulose and waxes. Typical lubricants for use in these dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine and polyethylene glycol. Suitable disintegrators can include, without limitation, starch, methylcellulose, agar, bentonite, cellulose, wood products, alginic acid, guar gum, citrus pulp, carboxymethylcellulose and sodium lauryl sulfate. If desired, a conventional pharmaceutically acceptable dye can be incorporated into the dosage unit form, i.e., any of the standard FD&C dyes.

Similarly, in a typical formulation for topical application, any one of the compounds of the instant invention is combined with triacetin, such that the active ingredient is present in an anti-inflammatory effective amount. The preparation is simply applied topically to the inflamed area, whereby the therapeutically active compound is dermally absorbed and "cleaved" to release the parent steroidal moiety at the site of inflammation.

Naturally, the therapeutic dosage range for the compounds of the instant invention will vary with the size and needs of the patient. However, generally speaking, the following dosage guidelines will suffice. On an oral basis, the therapeutic dose required for a compound of the instant invention will generally, on a molecular basis, mimic that for the parent conventional steroid moiety [e.g., cortisone, hydrocortisone, prednisone, prednisolone, etc.]. On a topical basis, application of a 0.01% to 2.5% concentration of a compound of the instant invention (in a suitable topical carrier material) to the site of inflammation should suffice.

While the invention has been described in terms of various preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3562255 *Apr 29, 1969Feb 9, 1971American Home Prod17-propargylamines of steroidal dithioketals
US3621014 *Jan 14, 1969Nov 16, 1971Hoechst Ag17{60 ,21-orthocarbonates of steroid derivatives
US4069322 *Oct 12, 1976Jan 17, 1978Interx Research CorporationPro-drugs for the improved delivery of certain selected anti-inflammatory steroids
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4443440 *Aug 30, 1982Apr 17, 1984The Upjohn CompanyAmine containing ester prodrugs of corticosteroids
US4456602 *Aug 23, 1982Jun 26, 1984The Upjohn CompanySolution stable antiinflammatory agents
US5886162 *Sep 23, 1991Mar 23, 1999Research Foundation Of State University Of New YorkLipophilic diakylaminomethylene prodrug derivatives for the inhibition of replication of viruses
US5908833 *Dec 13, 1996Jun 1, 1999Aktiebolaget AstraGlucocorticosteroid chemically bound to a sugar
US6140308 *Mar 3, 1999Oct 31, 2000Aktiebolaget AstraColon or ileum-specific glucocorticosteroid derivatives
US7101866Aug 3, 2001Sep 5, 2006Glaxo Group Limited6,9-Difluoro-17 alpha -((2-furanylcarbonyl)oxy)-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; antiinflammatory agents for the treatment of allergic conditions
US7125985Jun 7, 2004Oct 24, 2006Glaxo Group LimitedCompounds useful in the manufacture of an anti-inflammatory androstane derivative
US7132532Jun 7, 2004Nov 7, 2006Glaxo Group LimitedCompounds useful in the manufacture of an anti-inflammatory androstane derivative
US7144845Jun 7, 2004Dec 5, 2006Glaxo Group LimitedCompounds useful in the manufacture of an anti-inflammatory androstane derivative
US7291608Apr 30, 2002Nov 6, 2007Glaxo Group LimitedAnti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
US7498321Aug 3, 2001Mar 3, 2009Glaxo Group Limited17β-carbothioate 17α-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US7531528Aug 13, 2004May 12, 2009Glaxo Group Limitedmixture of aqueous carrier liquid containing dissolved glucocorticoid and 3-oxoandrostane carbothioic coompound
US7541350Aug 13, 2004Jun 2, 2009Glaxo Group LimitedFormulation containing anti-inflammatory androstane derivative
US7592329Feb 4, 2003Sep 22, 2009Glaxo Group Limitedcontaining an anti-inflammatory and anti-allergic compound of the androstane series
US7629335Jul 6, 2006Dec 8, 2009Glaxo Group Limitedcomprising a drug compound 6 alpha ,9 alpha -Difluoro-17 alpha -[(2-furanylcarbony)oxy]-11 beta -hydroxy-16 alpha -methyl-3-oxo-androsta-1,4-diene-17 beta -carbothioic acid S-fluoromethyl ester; dry powder inhaler; with predictable pharmacokinetic and pharmacodynamic behaviour
US7649022Mar 28, 2008Jan 19, 2010Medivas, LlcElastomeric polymer networks and semi-interpenetrating networks in which a linear poly(ester amide), poly(ester urethane), or poly(ester urea) polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species
US8163723Sep 10, 2010Apr 24, 2012Cipla LimitedCombination of azelastine and steroids
US8168620Jun 13, 2003May 1, 2012Cipla LimitedCombination of azelastine and steroids
US8304405Jul 23, 2009Nov 6, 2012Cipla LimitedCombination of azelastine and ciclesonide for nasal administration
US8318709Jul 23, 2009Nov 27, 2012Cipla LimitedCombination of azelastine and mometasone for nasal administration
US8652504Sep 21, 2006Feb 18, 2014Medivas, LlcSolid polymer delivery compositions and methods for use thereof
US20110027379 *Dec 4, 2008Feb 3, 2011Cornell UniversityOligo-Ethylene Glycol-Based Polymer Compositions and Methods of Use
EP0057401A1 *Jan 25, 1982Aug 11, 1982Schering CorporationAromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
EP0106453A1 *Aug 18, 1983Apr 25, 1984The Upjohn Company21-Hydroxycorticosteroid esters, and compositions containing them
EP0120557A2 *Jan 19, 1984Oct 3, 1984The Upjohn Company21-Hydroxycorticosteroid esters, and compositions containing them
WO2008058156A2 *Nov 6, 2007May 15, 2008Jina Pharmaceuticals IncGuggulphospholipid methods and compositions
WO2008121895A1 *Mar 28, 2008Oct 9, 2008Giorgi ChumburdzeBioabsorbable elastomeric polymer networks, cross-linkers and methods of use
WO2009011938A1 *Mar 28, 2008Jan 22, 2009Kenneth W CarpenterBioabsorbable elastomeric arterial support device and methods of use
WO2013074988A1 *Nov 16, 2012May 23, 2013The Regents Of The University Of Colorado, A Body CorporateMethods and compositions for enhanced drug delivery to the eye and extended delivery formulations
Classifications
U.S. Classification514/176, 514/180, 540/63, 514/179, 540/67, 540/70, 540/110
International ClassificationC07D295/185, C07J43/00, C07J41/00
Cooperative ClassificationC07J41/005, C07J43/003, C07D295/185
European ClassificationC07J43/00B, C07J41/00C6, C07D295/185